July 2025 updates to the Universal Influenza Vaccine Technology Landscape include the following:
- Preclinical evaluation of sequential vaccination with a conserved HA stalk-focused vaccine (group 2 chimeric HA inactivated split vaccine) and an adjuvanted recombinant NA protein (rNA-N2-MPP), reported in Puente-Massaguer 2025
- Results of a phase 1b randomized, double-blind, placebo-controlled trial of the safety, reactogenicity, and immunogenicity of FluGen’s intranasal M2SR H3N2 next-generation influenza vaccine in children, posted in NCT04960397
- Preclinical evaluation of broadly protective immune responses elicited by computationally optimized broadly-reactive H1 and H3 antigens expressed from a self-amplifying mRNA vector platform (samRNA-COBRA), reported in Pierce 2025
- Moderna reported safety and immunogenicity results from a phase 1/2 trial (NCT05333289) of mRNA-based next-generation influenza vaccine candidates (mRNA-1020 and mRNA-1030) encoding HA and NA antigens at different HA:NA ratios in Rudman Spergel 2025
- Relative vaccine efficacy against influenza illness elicited by Moderna’s mRNA-1010 next-generation candidate, compared with licensed seasonal influenza vaccine, in a randomized controlled phase 3 trial (NCT06602024) in 40,805 adults aged 50 and older in 11 countries, reported in a 6/30/25 press release; Moderna plans to publish the data in a peer-reviewed journal and submit an application for regulatory approval
- Preliminary safety, immunogenicity, and reactogenicity data from a phase 3 trial of Novavax’s combination COVID+influenza nanoparticle vaccine candidate (CIC) and next-generation influenza vaccine candidate (Nano-Flu, tNIV) in adults aged 65 and older, reported in a 6/11/25 press release
- Preclinical evaluation of mucosal and systemic humoral and cellular immune responses induced by intranasal administration of an adjuvanted recombinant NA-based influenza vaccine candidate, rNA-N1-MPP, reported in Vasilev 2025
- Preclinical evaluation of broadly protective immune responses induced by mucosal immunization with conserved NP antigens from influenza A and B viruses linked to the autophagy-inducing peptide C5 based on a bovine adenoviral vector, reported in Wang 2025
For more recent updates and additional information, see the Landscape.